Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions
BDTX Stock Forecast
Black Diamond Therapeutics stock forecast is as follows: an average price target of $14.75 (represents a 393.31% upside from BDTX’s last price of $2.99) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
BDTX Price Target
BDTX Analyst Ratings
Black Diamond Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 31, 2024 | Laura Prendergast | Raymond James | $20.00 | $5.91 | 238.41% | 568.90% |
Jun 03, 2024 | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | 150.84% | 301.34% |
May 16, 2024 | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | 102.21% | 267.89% |
Apr 08, 2024 | Robert Driscoll | Wedbush | $16.00 | $5.06 | 216.21% | 435.12% |
Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | 155.32% | 301.34% |
Black Diamond Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 5 |
Avg Price Target | - | - | $14.20 |
Last Closing Price | $2.99 | $2.99 | $2.99 |
Upside/Downside | -100.00% | -100.00% | 374.92% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jul 30, 2024 | Raymond James | - | Outperform | Initialise |
Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 08, 2024 | Wedbush | Outperform | Outperform | Hold |
Jun 28, 2023 | H.C. Wainwright | - | Buy | Upgrade |
Jun 27, 2023 | Wedbush | - | Outperform | Upgrade |
Black Diamond Therapeutics Financial Forecast
Black Diamond Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-19.78M | $-19.36M | $-18.45M | $-17.76M | $-19.43M | $-20.59M | $-21.34M |
High Forecast | $-19.78M | $-19.36M | $-18.45M | $-17.76M | $-19.43M | $-18.37M | $-21.34M |
Low Forecast | $-19.78M | $-19.36M | $-18.45M | $-17.76M | $-19.43M | $-22.82M | $-21.34M |
Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-0.36 | $-0.35 | $-0.33 | $-0.32 | $-0.35 | $-0.37 | $-0.39 |
High Forecast | $-0.36 | $-0.35 | $-0.33 | $-0.32 | $-0.35 | $-0.33 | $-0.39 |
Low Forecast | $-0.36 | $-0.35 | $-0.33 | $-0.32 | $-0.35 | $-0.41 | $-0.39 |
Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
BDTX Forecast FAQ
Is Black Diamond Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Black Diamond Therapeutics (BDTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of BDTX's total ratings.
What is BDTX's price target?
Black Diamond Therapeutics (BDTX) average price target is $14.75 with a range of $11 to $20, implying a 393.31% from its last price of $2.99. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Black Diamond Therapeutics stock go up soon?
According to Wall Street analysts' prediction for BDTX stock, the company can go up by 393.31% (from the last price of $2.99 to the average price target of $14.75), up by 568.90% based on the highest stock price target, and up by 267.89% based on the lowest stock price target.
Can Black Diamond Therapeutics stock reach $4?
BDTX's average twelve months analyst stock price target of $14.75 supports the claim that Black Diamond Therapeutics can reach $4 in the near future.
What are Black Diamond Therapeutics's analysts' financial forecasts?
Black Diamond Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-61.364M (high $-59.138M, low $-63.59M), average SG&A $0 (high $0, low $0), and average EPS is $-1.113 (high $-1.072, low $-1.153). BDTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.349M (high $-75.349M, low $-75.349M), average SG&A $0 (high $0, low $0), and average EPS is $-1.366 (high $-1.366, low $-1.366).